Anna Belser
Clinical Researcher
Data updated
Papers
Trials
Research Footprint
Anna Belser appears in 9 tracked papers (2016–2023), most studied alongside Psilocybin, MDMA and Ayahuasca, across Depressive Disorders, Anxiety Disorders and Palliative & End-of-Life Distress.
Most-cited paper: Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: A randomized controlled trial (1678 citations).
Frequent co-authors: Gabrielle Agin-Liebes, Stephen Ross and James Guss.
Background & Research
Anna Belser (publishes as A. B. Belser) is a clinical researcher whose work centres on the experiential, therapeutic and procedural aspects of psychedelic-assisted psychotherapy. Her publications focus on qualitative and small-sample clinical investigations of psilocybin-assisted therapy for cancer-related distress and anxiety, including detailed case series and interpretative phenomenological analyses that probe patients' subjective responses and meaning-making processes. Belser has explored the phenomenology of mystical-type experiences both inside and outside pharmacologically induced states and has contributed to methodological and theoretical work on models of psychedelic-assisted psychotherapy.
Her contributions extend beyond patient narratives to the pragmatic organisation of therapeutic approaches: she is an author on contemporary assessments of psychedelic-assisted psychotherapy models and an introducer to EMBARK, a transdiagnostic, trans-drug psychotherapy framework. Belser's research is characterised by rigorous qualitative methods, careful attention to clinical context in oncology settings, and an orientation toward translating subjective patient experiences into frameworks that inform therapeutic practice and trial design.
Key Impact
Notable for qualitative and conceptual contributions to the study of psilocybin-assisted psychotherapy, particularly in understanding patient experience and in advancing transdiagnostic psychotherapy models.
Collaboration Network
18 collaborators· click a node to visit their profile
Full network →Compounds
Topics
Top Collaborators
Affiliations
Institutions, companies, and organisations Anna Belser is associated with.
New York University
academicThe Center for Psychedelic Medicine at NYU Langone Health is directed by Dr. Michael Bogenschutz and performs health-focused research across the translational spectrum, from basic science to large-phase clinical trials. The center has three transdisciplinary areas of focus: psychiatry, medicine, and preclinical research. Currently, the team is actively investigating clinical applications for various psychedelic compounds, leading robust studies on psilocybin-assisted therapy for alcohol use disorder, major depression, and advanced cancer-related psychiatric distress.
View stakeholder →COMPASS Pathways
Public BiotechCOMPASS Pathways is a UK-listed biopharmaceutical company developing COMP360 synthetic psilocybin therapy for treatment-resistant depression, with two successful Phase 3 trials making it the leading candidate for the first regulatory approval of a classic psychedelic medicine.
View stakeholder →Cybin
biotechCybin Inc. (founded 2019) is a Canadian clinical-stage biopharmaceutical company developing psychedelic-based therapeutics—now operating as Helus Pharma—focused on proprietary novel serotonergic agonists and deuterated psilocin analogs for mental health conditions.
View stakeholder →